Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Stock Chart & Stats
$100.54
-$0.27(-0.64%)
At close: 4:00 PM EST
$100.54
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$36.88 - $105.74
Previous CloseN/A
Volume92.82K
Average Volume (3M)757.15K
Market Cap
$5.22B
Enterprise Value$5.18B
Total Cash (Recent Filing)$375.55M
Total Debt (Recent Filing)$318.76M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Mar 11, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding51,683,838
10 Day Avg. Volume751,551
30 Day Avg. Volume757,148
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)8.71
Price to Sales (P/S)5.83
P/FCF Ratio210.57
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue10.98
Enterprise Value/Gross Profit13.74
Enterprise Value/Ebitda-944.19
Forecast
1Y Price Target
$114.20Price Target Upside13.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$631.15M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentInterim analyses of volixibat mid-stage studies met predefined efficacy and safety thresholds and an independent committee recommended expansion to confirmatory studies, supporting a potential regulatory filing if topline confirmatory data are positive.
Commercial Execution And GuidanceReported revenue outperformance, positive operating cash flow and raised revenue guidance indicate solid commercial execution and reinforce the company’s ability to leverage existing commercial infrastructure and hepatology key opinion leader relationships for product launches.
Pipeline Expansion And Regulatory DesignationsAcquisition of Bluejay adds brelovitug, a candidate with robust Phase 2 virologic responses and regulatory breakthrough designations, enhancing the rare liver disease pipeline and strengthening late-stage program prospects.
Bears Say
ANDA Challenge To Patent ValidityAn ANDA filing seeks to invalidate method-of-treatment patents covering the lead product, raising the risk that patents could be overturned and generic approval could proceed, which would pressure pricing and market share.
Multiple Generic Filer RiskExpectation of additional generic filers increases the likelihood of prolonged legal disputes and competitive entry once legal barriers resolve, potentially accelerating market erosion and raising legal expenses.
Patent Litigation RiskReceipt of a Paragraph IV notification initiates patent litigation and exposes the company to a costly legal battle that could create uncertainty around exclusivity and future product revenues.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $36.88 and its highest was $105.74 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $5.22B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Mar 11, 2026 which is in 27 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.19.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is 0.04.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 51,683,838 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -1.24%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.20 (13.59% Upside)
$114.20 (13.59% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.90%
12-Months-Change
Fundamentals
Return on Equity
-15.81%
Trailing 12-Months
Asset Growth
17.55%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals had a strong third quarter with significant revenue growth and positive net income for the first time. The company continues to advance its clinical pipeline and expand internationally. However, there are some challenges in revenue consistency and the adoption of genetic testing in certain segments.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$114.20
▲(13.59% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Ownership Overview
Currently, No data available
---